After Cantor Fitzgerald and J.P. Morgan gave Eli Lilly & Co (NYSE: LLY) a Buy rating last month, the company received another Buy, this time from Barclays. Analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co today and set a price target of $120. The company’s shares closed yesterday at $107.91.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 4.8% and a 53.5% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Alexion Pharmaceuticals, and United Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eli Lilly & Co with a $111.45 average price target, implying a 3.3% upside from current levels. In a report issued on October 8, Guggenheim also initiated coverage with a Buy rating on the stock with a $132 price target.
The company has a one-year high of $116.61 and a one-year low of $73.69. Currently, Eli Lilly & Co has an average volume of 4.03M.
Based on the recent corporate insider activity of 132 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.